NCT02899936View on ClinicalTrials.gov

Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis

NACompletedINTERVENTIONAL
Enrollment

23,789

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 27, 2017

Study Completion Date

May 31, 2018

Conditions
Lymphatic Filariasis
Interventions
DRUG

3 drug dose - IDA

Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)

DRUG

2 drug dose - DA

Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)

Trial Locations (4)

605006

Vector Control Research Centre, Puducherry

Unknown

Ministere de la Sante Publique et de la Population, Port-au-Prince

Universitas Indonesia, Jakarta

Papua New Guinea Institute for Medical Research, Madang

All Listed Sponsors
collaborator

Case Western Reserve University

OTHER

collaborator

Indian Council of Medical Research

OTHER_GOV

lead

Washington University School of Medicine

OTHER

NCT02899936 - Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis | Biotech Hunter | Biotech Hunter